This review provides a practical, clinician-oriented guide to the statistical principles and advanced methods for developing, validating, and interpreting robust prediction models and synthesized key statistical principles and illustrative examples to guide clinicians and researchers through model development, validation, interpretation, and clinical translation.
Abstract
Background Prediction models are central to advancing precision oncology, yet many fail to translate into clinical practice due to methodological flaws and inadequate validation. This review provides a practical, clinician-oriented guide to the statistical principles and advanced methods for developing, validating, and interpreting robust prediction models. Methods This narrative review used a targeted literature search of PubMed, Embase, and Web of Science to identify methodological papers, reporting guidelines, and representative oncology prediction model studies, with a focus on literature published between January 1, 2005, and February 28, 2025. Landmark methodological papers published before 2005 were also included when directly relevant. Rather than performing a systematic review or meta-analysis, we synthesized key statistical principles and illustrative examples to guide clinicians and researchers through model development, validation, interpretation, and clinical translation. Findings A multifaceted evaluation encompassing discrimination, calibration, clinical utility, and external validation is essential for prediction models. Over-reliance on discrimination metrics such as the area under the receiver operating characteristic curve (AUC), while neglecting calibration and clinical utility, can lead to misleading conclusions about a model’s value. Rigorous external validation in geographically or temporally distinct cohorts is the most direct test of generalizability, and performance degradation should be interpreted through root-cause analysis rather than treated simply as model failure. Key challenges include managing overfitting, selecting appropriate modeling and validation strategies for different oncology scenarios, addressing special settings such as rare tumors and real-world data, and improving the interpretability of complex “black-box” models. Conclusion Building a trustworthy prediction model requires a combination of advanced computational methods and rigorous statistical principles. To bridge the gap from model development to clinical impact, researchers must prioritize comprehensive validation, transparent reporting, scenario-appropriate modeling decisions, and critical assessment of a model’s real-world utility.
BACKGROUND
External validation is essential for assessing the generalisability and transportability of a clinical prediction model. A previous review of studies published in 2010 identified substantial deficiencies in the reporting of external validations. In 2015, the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement was introduced, though its impact is unclear. Although external validation is widely recommended, its prevalence in recent oncology prediction model studies is uncertain, despite the large number of models developed in this field. We aimed to examine the proportion of oncology prediction model studies including an external validation and the reporting completeness of these studies, providing a cross-sectional overview of current practice.
METHODS
We searched MEDLINE (via OVID) for primary studies published between 1 June and 31 July 2023. Eligible studies evaluated multivariable prediction models in oncology using data not used for model development, including temporal or geographical split-sample approaches. Reporting completeness was assessed using the TRIPOD statement. Screening and data extraction were performed in duplicate. Findings were summarised using counts and percentages.
RESULTS
Of 287 eligible oncology-based prediction model studies, 89 (31%) included an external validation component, with only three studies (1%) performing external validation without model development. Most validations (78/89, 88%) were conducted on newly developed models within the same study, and 32/89 (36%) used temporal or geographical split-sample approaches. Study design and participant characteristics were frequently reported, but outcome and predictor definitions were complete in only 64% and 46% of studies, respectively. Only one study reported a sample size calculation. Performance measures were reported with confidence intervals in 52/89 (58%). Calibration was assessed in 57/89 (64%), and clinical utility in 33/89 (37%). Only 22/89 (25%) explicitly described how predictions were calculated in the validation dataset. Despite validation data being clustered in 31/89 studies, heterogeneity across centres or subgroups was never examined. Open science practices were uncommon, including study registration (2.2%), protocol availability (1.1%), and code sharing (4.5%).
DISCUSSION
In this two-month cross-sectional snapshot in 2023, external validation studies were substantially less common than prediction model development studies and reporting of key methodological and performance details were frequently incomplete despite the availability of TRIPOD. External validation was often reported without clear articulation of its objectives or contextualisation of model performance, suggesting it may sometimes be treated as a procedural step rather than a study designed to evaluate model transportability. Greater emphasis on transparently reporting external validation studies is required to enable reliable evaluation and comparison of prediction models.
Rebecca Whittle, A. Legha, Biruk Tsegaye et al.· Journal of Clinical Epidemio...· 0 citations
PURPOSE OF REVIEW
Clinical models are commonly applied in critical care for both descriptive and predictive purposes. However, methodological rigour is often lacking in their development and validation. This review examines the principles underlying the multiple domains of model validity. We argue that a clear model purpose and theoretical framework are essential preconditions for validity.
RECENT FINDINGS
Recently developed descriptive and predictive models illustrate different approaches to promoting validity. In developing SOFA-2, eCARTv5, Sepsis-3 and the PHOENIX paediatric sepsis criteria, authors used combinations of expert-driven consensus, data-driven derivation and iterative refinement. These examples demonstrate that validity requires a process of repeated evaluation across distinct populations, settings and time periods.
SUMMARY
The best approach to establishing validity combines a clear theoretical framework, structured expert consensus (including Delphi methodology), rigorous statistical evaluation (discrimination, calibration, net benefit) and prospective external validation. The distinction between models designed to predict outcomes and those designed to describe or quantify organ dysfunction is fundamental and should guide development and validation strategy from the outset.
A. Tracy, Aasiyah Rashan, O. Ranzani· Current Opinion in Critical...· 0 citations
In oncology, interpreting clinical trials solely through statistical significance (P < .05) often conflates true biological futility with methodological false negatives. This binary oversimplification risks prematurely abandoning active therapies while wasting resources on futile programs. We aimed to develop a structured framework to evaluate late-phase trials beyond simple P value assessments. Through a critical review of literature and landmark late-phase oncology trials, we analyzed common failure mechanisms and methodological pitfalls to construct a comprehensive, three-step methodology for the post hoc evaluation of negative studies. The review yielded a synthesized framework that approaches trial interpretation through three sequential steps. First, classification stratifies trials into five distinct categories: true negatives, false negatives, inconclusive trials, positive but irrelevant results, and nonsuperior but clinically valuable. Second, diagnosis uses root-cause analysis to identify underlying trial design flaws, execution biases, or statistical pitfalls. Third, recommendations outline targeted actionable strategies, including trial redesign, supplementary biomarker validation, precision medicine approaches, or scientific confirmation of therapeutic futility. This framework shifts trial interpretation from a simple win/loss assessment to a nuanced, value-based strategy. By systematically dissecting the root causes of trial failures, it empowers researchers to rescue therapies with latent clinical benefit or confidently confirm futility, thereby optimizing the evidence landscape for precision oncology.
Ruyue Li, Xue Dong, Xiujing Yao et al.· JCO Precision Oncology· 0 citations
Background and Objective: Studies examining the association between cancer diagnosis to treatment interval (DTI) and overall survival (OS) are important to help inform clinical practice guidelines. Recent international consensus-based recommendations defined best practices for this area of research and raised concerns about the poor validity and inconsistent methodologies in the available literature. Our objective is to systematically assess the quality of studies investigating the association between DTI and OS using consensus-based methodological recommendations. Methods: We are conducting a systematic review of observational studies published from 2020 onward that examine the association between DTI and OS in seven cancers with global relevance: bladder, breast, colon, rectal, lung, cervical, and head and neck cancers. We developed thorough search strategies to search Ovid MEDLINE, EMBASE, and Web of Science databases. Two rounds of screening will be performed in tandem using Covidence following predefined exclusion criteria and reliability procedures. Data extraction will be performed using Covidence with considerations for reliability and reconciliation. Methodological components will be evaluated against international consensus-based recommendations across domains including variable definition and measurement, cohort creation, confounder control, bias management, analytic techniques, and responsible data interpretation. Findings will be synthesized and presented using descriptive statistics. Anticipated Applications: This review will provide a comprehensive assessment of methodological validity and consistency in recent studies investigating the association between cancer DTI and OS. The findings will highlight areas for improvement and support wider adoption of the consensus-based recommendations to strengthen future research in this area (Jalink et al., 2025).
References: Jalink M, King WD, Anderson BO, et al. Recommendations for studying the association of the cancer diagnosis to treatment interval with overall survival: a modified Delphi process. Br J Cancer. 2025;133:1526-1534. doi:10.1038/s41416-025-03158-3.
V. Patel· Inquiry@Queen's Undergraduat...· 0 citations
BACKGROUND
Predictive modelling for cancer risk, treatment-related complications, and survival is central to precision oncology. Conventional logistic regression (LR) and Cox proportional hazards (CoxPH) regression remain widely used but are limited when modelling nonlinear interactions, high-dimensional imaging features, and multimodal clinical-metabolic predictors. Artificial intelligence (AI) and machine learning (ML) methods offer expanded capability through automated feature extraction, ensemble learning, and flexible survival modelling, but the evidence on when AI/ML adds value over conventional models across cancer sites and predictive tasks remains fragmented.
OBJECTIVE
To systematically evaluate the methodological performance, validation strategies, and translational limitations of AI/ML models compared with conventional statistical models in published predictive-modelling studies for breast, colorectal, or pancreatic cancer.
METHODS
PubMed, Scopus, and Web of Science were searched for studies published between January 2019 and March 2025. Two reviewers independently conducted title-and-abstract screening, full-text eligibility assessment, and PROBAST risk-of-bias assessment. Sixty-five studies (n = 907,567 participants) were narratively synthesised by cancer site, predictive task, model family, comparator, validation strategy, predictor modality, and calibration or explainability reporting.
RESULTS
The 65 studies comprised breast cancer (n = 35), colorectal cancer (n = 21), and pancreatic cancer (n = 9). AI/ML superiority over LR and CoxPH was task- and data-dependent. CNN- and U-Net-based models predominated in imaging and body-composition tasks, tree-based ensembles consistently outperformed LR for tabular perioperative complication prediction, and CoxPH remained competitive, and in the largest pancreatic risk study, superior to XGBoost (C-index 0.802 vs 0.723) in well-structured datasets. PROBAST analysis-domain risk was moderate in 54 of 65 studies (83%), driven by limited external validation, sparse calibration reporting (11/65), and few decision-curve analyses (7/65).
CONCLUSION
AI/ML adds the most methodological value in imaging-derived feature extraction and nonlinear perioperative prediction, while conventional regression remains preferable in large, structured datasets with linear predictors. Clinical translation requires standardised body-composition definitions, external validation, calibration assessment, decision-curve analysis, and explainability, in line with TRIPOD+AI and CLAIM standards.
N. Z. Abidin, N. Shariff, Eva Nabiha Zamri et al.· Artificial Intelligence in M...· 0 citations
Background While health technology assessment (HTA) acceptance of contextual real-world data (RWD) studies describing burden of disease, disease natural history, or treatment pathways is relatively common, HTA practices for RWD studies addressing real-world clinical efficacy, such as those using external control arms (ECAs), are still evolving and less standardized. The aim of this study was to use data from HTA submissions and reports to understand common analytical methods and data considerations for submissions using RWD-based ECA. This evaluation used ECA studies as a basis for investigating the use of RWD to evaluate clinical efficacy. Methods Secondary data were compiled from selected oncology submissions to HTA agencies between January 2016 and December 2022 that incorporated RWD-based ECA data, using natural language-processing text-mining to identify and select relevant cases. Submissions were reviewed in six countries across Asia Pacific (Australia), Europe (France, Germany, UK), and North America (Canada and US). Submissions that were rated both positive and negative by HTA agencies were included, with HTA feedback organized into generalizability, confounding, data quality, and data analysis categories. Results Of 204 submissions identified, 100 cases were selected for the analysis of patterns highlighting sources of data for ECAs and RWD methodology best practices: Australia (n = 3), Canada (n = 34), France (n = 19), Germany (n = 15), UK (n = 26), and US (n = 3). A positive HTA recommendation was received by 69 of these 100 cases. Lung cancer was associated with the greatest number of cases/submissions. Retrospective cohort studies were the most common source of RWD, with inverse probability of treatment weighting/propensity score weight as the most common methodology used to generate real-world evidence. Most of the selected RWD-based ECA cases were from Canadian and UK HTA agencies. Positive comments focused on population adjustment, RWD viability, and alignment of data with standard of care (SoC) for that country/indication; negative comments focused on missing/limited data, lack of alignment with SoC, and potential risk of bias. Conclusion This study captured challenges in considering RWD-based ECAs for HTA submission and presents criteria for creating viable RWD studies using ECAs. Data source selection, patient population comparison, and transparent presentation of potential biases were important factors in enhancing the credibility and utility of RWD-based ECAs in HTA decision-making processes.
Gleicy Macedo Hair, M. Hanisch, S. Mt-Isa et al.· Oncology Reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
